Skip to main content

REVIEW article

Front. Genet.
Sec. Epigenomics and Epigenetics
Volume 15 - 2024 | doi: 10.3389/fgene.2024.1431564

TRIM28 in cancer and cancer therapy

Provisionally accepted
Kailang Li Kailang Li 1Haifeng Wang Haifeng Wang 1Bitao Jiang Bitao Jiang 1*Xiaofeng Jin Xiaofeng Jin 2*
  • 1 Beilun District People's Hospital of Ningbo, Ningbo, Zhejiang Province, China
  • 2 Ningbo University, Ningbo, Zhejiang Province, China

The final, formatted version of the article will be published soon.

    TRIM28 (tripartite motif protein 28) was initially believed to be a transcription inhibitor that plays an important role in DNA damage repair (DDR) and in maintaining cancer cellular stemness. As research has continued to deepen, several studies have found that TRIM28 not only has ubiquitin E3 ligase activity to promote degradation of substrates, but also can promote SUMOylation of substrates. Although TRIM28 is highly expressed in various cancer tissues and has oncogenic effects, there are still a few studies indicating that TRIM28 has certain anticancer effects. Additionally, TRIM28 is subject to complex upstream regulation. In this review, we have elaborated on the structure and regulation of TRIM28. At the same time, highlighting the functional role of TRIM28 in tumor development and emphasizing its impact on cancer treatment provides a new direction for future clinical antitumor treatment

    Keywords: Trim28, Ubiquitination, Sumoylation, Transcription inhibitor, tumorigenesis, cancer therapy

    Received: 12 May 2024; Accepted: 01 Jul 2024.

    Copyright: © 2024 Li, Wang, Jiang and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Bitao Jiang, Beilun District People's Hospital of Ningbo, Ningbo, 315800, Zhejiang Province, China
    Xiaofeng Jin, Ningbo University, Ningbo, 315211, Zhejiang Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.